more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Zacks News

Gilead Down on Suspension of Coronavirus Study in China

by Zacks Equity Research Published on April 16,2020

Gilead (GILD) declines after a study on investigational antiviral, remdesivir, was suspended in China due to the lack of eligible patients.

Top Research Reports for Comcast, Bristol-Myers & Walgreens

by Mark Vickery Published on April 16,2020

Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Bristol-Myers Squibb (BMY) and Walgreens Boots Alliance (WBA).

Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis

by Zacks Equity Research Published on April 15,2020

The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

biotechs

Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine

by Zacks Equity Research Published on April 15,2020

Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.

pharmaceuticals

Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy

by Kinjel Shah Published on April 15,2020

Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.

pharmaceuticals

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

by Ritujay Ghosh Published on April 15,2020

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure

by Sweta Jaiswal, FRM Published on April 14,2020

Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.

SNY vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on April 14,2020

SNY vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Progressing Well With its Coronavirus Program

by Zacks Equity Research Published on April 13,2020

Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.

pharmaceuticals

Lilly Announces Clinical Study Plans for Coronavirus Disease

by Zacks Equity Research Published on April 13,2020

Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.

pharmaceuticals

Gilead Reports Promising Data on Experimental Coronavirus Drug

by Zacks Equity Research Published on April 13,2020

Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.

Is Sanofi (SNY) a Great Value Stock Right Now?

by Zacks Equity Research Published on April 09,2020

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

SNYPositive Net Change

Sanofi (SNY) Gains But Lags Market: What You Should Know

by Zacks Equity Research Published on April 08,2020

In the latest trading session, Sanofi (SNY) closed at $45.18, marking a +1.3% move from the previous day.

SNYPositive Net Change

Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA

by Zacks Equity Research Published on April 08,2020

Alnylam (ALNY) completes rolling submission of the NDA for lumasiran seeking approval for kidney disease, primary hyperoxaluria type 1. The EMA accepts MAA for lumasiran for the same indication.

biotechs

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM Published on April 07,2020

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Esperion's Cholesterol Drugs Receive Approval in Europe

by Zacks Equity Research Published on April 07,2020

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.

biotechs

Coronavirus Progress Boosts Investors' Sentiments

by Zacks Equity Research Published on April 07,2020

Coronavirus Progress Boosts Investors' Sentiments.

Gilead Partners Second Genome, Boosts Coronavirus Drug Production

by Zacks Equity Research Published on April 07,2020

Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.

biotechs

Markets Bullish on Coronavirus Progress

by Mark Vickery Published on April 07,2020

"Flattening the curve" measures are beginning to bear fruit, as are announcements from myriad pharmaceutical companies vying to develop near-term therapeutics and longer-term vaccines for the coronavirus.

medical

Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

by Kinjel Shah Published on April 07,2020

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.